Navigation Links
AngelMD Investor Group Closes Second Round of Funding in Noninvasix
Date:1/8/2019

Today AngelMD announced that it completed a syndicate investment comprised of its members into Noninvasix. This represents the second investment AngelMD has made into Noninvasix in the past year.

To reduce the incidence of neonatal mortality and morbidity, Noninvasix is developing a patient monitor to directly, accurately, and noninvasively measure brain oxygenation in preterm babies in the NICU. Early detection of inadequate brain oxygenation will allow neonatologists to intervene before cerebral function is permanently compromised.

Leading the AngelMD syndicate of investors was Jagjit Khairah, DO, FACOG, Department of Obstetrics & Gynecology, Kelsey Seybold Clinic who had this to say about Noninvasix: “The technological advances used with by Noninvasix to detect levels of oxygenation without needing a blood sample is remarkable. To have instant results using acoustic and laser sensor related probes will enable health care teams across many specialties of medicine to expedite critical care. Graham and his team have an amazing vision and are poised to help us change the way we address the needs of our patients on many fronts using this innovative technology.”

“Raising money through AngelMD is basically raising money from our future users. These are the people who understand best how Noninvasix’s technology can be a solution to some of their biggest issues.” said Graham Randall, CEO Noninvasix. “While we value all capital investment, having a group of engaged and supportive physicians backing us brings value well beyond the money.”

About Noninvasix

Noninvasix is developing non-invasive precision oximetry, which will allow doctors for the first time to accurately monitor oxygen sufficiency within organs without invasive catheters. Inadequate organ oxygenation is a major cause of death and permanent disability in hospitals. Prompt recognition of low venous oxygenation can be used to guide therapeutic interventions and reduce adverse outcomes.

With patented optoacoustic technology at its core, Noninvasix’s system consists of a disposable probe that can be worn on the head, chest or wrist — depending on the desired metric — and a display console.

Noninvasix's undertaking is backed by 15 years of optoacoustic research by its co-founders, more than $6.5 million in research grants, 9 patents, and validation in peer-review journal articles.

For more information, visit http://noninvasix.com/

About AngelMD

AngelMD, an online Healthcare Investment and Innovation Marketplace, connects and engages a network of physicians, angel investors, early stage healthcare companies and subject matter experts through a powerful technology platform to create better outcomes for patients and investors. For more information, visit http://www.angelmd.co

Read the full story at https://www.prweb.com/releases/angelmd_investor_group_closes_second_round_of_funding_in_noninvasix/prweb16018138.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. angelMD Completes Investment in Bleeding Detection Medical Device Company
2. 3 angelMD Startups Make Livestrong Big C Semi-finals
3. Brainstorm Cell Therapeutics to Present at ARMs 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston
4. Audentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
5. Viking Therapeutics to Present at H.C. Wainwright & Co.s 1st Annual NASH Investor Conference
6. Biotech Stocks on Investors Radar -- Portola Pharma, OvaScience, Ocera Therapeutics, and Ocular Therapeutix
7. NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors
8. Capricor Therapeutics to Present at Two Investor Conferences in March
9. Relmada Therapeutics to Participate in BIO CEO and Investor Conference
10. Biotech Stocks on Investors Radar -- Amicus Therapeutics, Cempra, Ophthotech, and Sarepta Therapeutics
11. Arcturus Therapeutics to Present at the 19th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2019)... N.C. (PRWEB) , ... May 30, 2019 , ... ... is the first to demonstrate an efficient delivery system for the sustained release ... injuries. The platelet-rich plasma-based gel system was able to deliver CM into the ...
(Date:5/15/2019)... (PRWEB) , ... May 15, 2019 , ... Milton Hershey ... in recognition for his work within the biomedical industry, where he is changing lives ... medical devices. , “William Harding epitomizes the vision of our founders – Milton ...
(Date:5/14/2019)... ... 14, 2019 , ... Gateway Genomics , a leading developer of prenatal ... to 5,000 square feet. , “This past year has seen exponential growth for ... CEO, Chris Jacob. “The SneakPeek At-Home test, which is mailed directly to our customers ...
(Date:5/4/2019)... ... May 03, 2019 , ... ... of the Dakila Pesquisas Association, the scientist and ufologist Urandir Fernandes de Oliveira, ... (DF). Urandir detailed the results of some research carried out by the association, ...
Breaking Biology Technology:
(Date:5/21/2019)... SCOTTSDALE, Ariz. (PRWEB) , ... May 20, 2019 , ... ... for a recent acclaimed documentary. The documentary, Stem Cell Therapy: Biotechnology to the Rescue, ... is an hour long, Dr. Greene was interviewed in regards to the safety of ...
(Date:5/21/2019)... ... 2019 , ... Pennsylvania College of Health Sciences, the area’s ... for first-time test takers of the National Council Licensure Examination (NCLEX) for the ... 20 points. , “This first-time pass rate is commendable and demonstrates the ...
(Date:5/16/2019)... ... ... In a FDA-contracted Standard Coordinating Body Workshop held at the National Institute ... founder and director James L. Sherley, M.D., Ph.D. predicted a sea change in ... Many of the gathered participants dismissed this idea. Few argued against the importance ...
Breaking Biology News(10 mins):